Yasin Keshvargar
Lawyers
Filters
AnHeart Therapeutics acquisition by Nuvation Bio
We are advising AnHeart Therapeutics on the acquisition
Borse Dubai $1.8 billion secondary offering of Nasdaq shares
We advised Borse Dubai on the offering
Beazer Homes USA $250 million notes offering
The high-yield notes are due 2031
Exchange transaction for Sabre exchangeable notes
We advised Sabre on its exchange of exchangeable senior notes
Sabre private exchange
We advised Sabre on its exchange of senior secured notes
Metagenomi $93.75 million IPO
The shares are listed on the Nasdaq Global Market
Eli Lilly $6.5 billion notes offering
The investment-grade notes are due 2027, 2029, 2034, 2054 and 2064
Immunocore Holdings $402.5 million convertible notes offering
The 2.5% convertible notes are due 2030
Immatics $201 million follow-on offering
We advised Immatics on the offering of shares
Solid Biosciences $109 million private placement
The PIPE includes common stock and pre-funded warrants